N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
Early Phase 1 N=4 High Frequency SARS for Neurogenic Bladder and Bowel Emptying
Spinal Cord Injury
Primary: Urethral Sphincter Pressure — 50 cmH2O
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 2 N=37 Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
N/A N=78 Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
Neurogenic Bladder · Lower Urinary Tract Symptoms · Overactive Bladder
Primary: Willingness to Repeat Procedure — 9.16; 9.34; 9.73; 9.67 units on a scale — p=0.57
N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
Phase 3 N=275 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes
Phase 4 N=24 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
Detrusor Hyperreflexia
Primary: Average Number of Catheterizations Without Leaking Per Day — 2.4; 1.5 Number of Dry Catheterizations per Day
N/A N=55 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Urinary Incontinence
Primary: Change From Baseline in Anticholinergic Drug Use — 305.21; 199.77 Doses of Anticholinergic Drugs
Phase 3 N=144 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Urinary Incontinence · Multiple Sclerosis · Neurogenic Bladder
Primary: Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes — 4.18; 4.32; -3.34; -1.10 Episodes
Phase 3 N=416 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes
Phase 3 N=21 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1)- Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 6 — -0.18; -3.20 Episodes
N/A N=31 Comparison of Motor and Sensory Response With Interstim Stimulation
Overactive Bladder · Urgency-Frequency
Primary: Percent of Symptoms With Improvement of Leaks Reported — 14.4; 19.8; 18.2 Percent change in leaks
N/A N=50 Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
Chronic Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Reduction in Bladder Medication — 19; 15 Participants
Phase 1 N=13 Colonizing Neurogenic Bladders With Benign Flora
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
N/A N=20 Amplifying Sensation in Underactive Bladder
Urinary Bladder, Underactive
Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1
N/A N=12 Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
Multiple Sclerosis · Lower Urinary Tract Symptoms · Neurogenic Bladder
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment — 2.6; 2.6; 3.5; 2.6 BOLD Signal Change Derived T-Value — p=0.0012
Phase 1 N=3 Two Devices for Reflex Voiding Following Spinal Cord Injury
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants
N/A N=16 Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation
Chronic Spinal Cord Injury · Neurogenic Bowel
Primary: Safety of Using TTNS at Home Daily as Indicated by Number of Adverse Events Recorded in Bladder Diary — 0 adverse events
N/A N=19 The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury
Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Infection — 4; 3 Participants
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 4 N=33 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Overactive Detrusor · Neurogenic Bladder
Primary: Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6 — -0.45; 16.91; 13.82; 15.32 percentage of point — p=0.0928
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 3 N=161 Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
Bladder, Neurogenic
Primary: Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day. — 35.3; 45.7…
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
N/A N=154 PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
Overactive Bladder
Primary: Change in Number of Urinary Urge Incontinence (UUI) Episodes Per Day After the 12th PTNM Therapy Sessions From Baseline — -2.4 UUI episodes per day — p=<0.0001